Oprelvekin

From WikiMD's medical encyclopedia

Information about Oprelvekin

Oprelvekin is a recombinant form of human interleukin 11, a cytokine that stimulates proliferation and maturation of bone marrow stem cells and megakaryocytes and is used to treat severe thrombocytopenia caused by chemotherapy.


Liver safety of Oprelvekin

Interleukin 11 therapy has not been linked to serum enzyme elevations or with instances of jaundice or clinically significant acute liver injury.


Mechanism of action of Oprelvekin

Oprelvekin (oh prel' veh kin") is a recombinant DNA form of interleukin 11, a human cytokine produced by bone marrow stromal cells that induces the proliferation and maturation of hematopoietic stem cells and megakaryocytes. While it stimulates several bone marrow lineages in rodents, IL-11 effects in humans are largely upon megakaryocytes, stimulating a robust increase in platelet counts. Recombinant forms of interleukin 11 have been developed and shown to have potent thrombopoietic activity.

FDA approval information for Oprelvekin

Oprelvekin was approved for use in the United States in 1997 and current indications are as prevention of severe thrombocytopenia and need for platelet transfusions in adults receiving myelosuppressive chemotherapy of non-myeloid malignancies. Oprelvekin is available as lyophilized powder in single use vials of 5 mg under the brand name Neumega. The typical dose is 50 µg/kg subcutaneously once daily for 10 to 21 days, usually starting within 6 to 24 hours of completing chemotherapy.

Side effects of Oprelvekin

Common side effects include the complications of sodium retention such as peripheral edema, dyspnea, pleural effusions, dilutional anemia, tachycardia and atrial arrhythmias. Other side effects include headache, fever, dizziness and syncope. Less common but potentially severe adverse reactions include severe arrhythmias, allergic reactions and anaphylaxis, capillary leak syndrome, optic neuropathy, papilledema, visual disturbances and renal failure. Hematologic Agents Eculizumab, Emapalumab, Emicizumab, Lanadelumab, Ravulizumab

Hematologic Growth Factors

  • Granulocyte-Macrophage Colony Stimulating Factors

Thrombopoietin receptor agonists and Thrombopoiesis Stimulators

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Transform your life with W8MD's budget GLP-1 injections from $125.

W8mdlogo.png
W8MD weight loss doctors team

W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:

NYC weight loss doctor appointments

Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.

Linkedin_Shiny_Icon Facebook_Shiny_Icon YouTube_icon_(2011-2013) Google plus


Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD